We are live on
!
Find out more
Lineage Cell Therapeutics
LCTX
LCTX
106 hedge funds and large institutions have $76.2M invested in Lineage Cell Therapeutics in 2022 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 24 increasing their positions, 23 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
1,975% more call options, than puts
Call options by funds: $83K | Put options by funds: $4K
31% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 13
4% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 23
4% more capital invested
Capital invested by funds: $73.1M → $76.2M (+$3.03M)
1% more funds holding
Funds holding: 105 → 106 (+1)
0.17% more ownership
Funds ownership: 38.14% → 38.32% (+0.17%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Holders
106
Holders Change
+1
Holders Change %
+0.95%
% of All Funds
1.7%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
17
Increased
24
Reduced
23
Closed
13
Calls
$83K
Puts
$4K
Net Calls
+$79K
Net Calls Change
-$92K
Top Buyers
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$681K |
| 2 |
Citigroup
New York
|
+$430K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$219K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$196K |
| 5 |
6CM
683 Capital Management
New York
|
+$162K |
Top Sellers
| 1 |
RA
Raffles Associates
New York
|
-$685K |
| 2 |
E
Ergoteles
New York
|
-$382K |
| 3 |
Two Sigma Advisers
New York
|
-$165K |
| 4 |
Millennium Management
New York
|
-$135K |
| 5 |
DC
Defender Capital
Charlotte,
North Carolina
|
-$114K |
